Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Surveillance User Fee Proposal Is Premature; PhRMA Responds To JAMA

Executive Summary

Discussion of ways to fund expanded post-marketing surveillance activities by FDA should await a clear assessment of the extent of the problem, the Pharmaceutical Research & Manufacturers of America said in response to a May 20 Journal of the American Medical Association article entitled "Time To Take Action on Drug Safety."

You may also be interested in...



Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer

The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers

Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer

The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers

FDA Risk Cmte. Includes “Cooperative Agreement” Grantee Gardner

FDA Drug Safety & Risk Management Subcommittee member Jacqueline Gardner, PhD, is a former grantee of the agency's cooperative agreement program to provide active surveillance data for the Office of Drug Safety

Related Content

UsernamePublicRestriction

Register

PS032237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel